<?xml version='1.0' encoding='utf-8'?>
<document id="29998365"><sentence text="Phase Ib trial combining capecitabine, erlotinib and bevacizumab in pancreatic adenocarcinoma - REBECA trial."><entity charOffset="25-37" id="DDI-PubMed.29998365.s1.e0" text="capecitabine" /><entity charOffset="39-48" id="DDI-PubMed.29998365.s1.e1" text="erlotinib" /><entity charOffset="53-64" id="DDI-PubMed.29998365.s1.e2" text="bevacizumab" /><pair ddi="false" e1="DDI-PubMed.29998365.s1.e0" e2="DDI-PubMed.29998365.s1.e0" /><pair ddi="false" e1="DDI-PubMed.29998365.s1.e0" e2="DDI-PubMed.29998365.s1.e1" /><pair ddi="false" e1="DDI-PubMed.29998365.s1.e0" e2="DDI-PubMed.29998365.s1.e2" /><pair ddi="false" e1="DDI-PubMed.29998365.s1.e1" e2="DDI-PubMed.29998365.s1.e1" /><pair ddi="false" e1="DDI-PubMed.29998365.s1.e1" e2="DDI-PubMed.29998365.s1.e2" /></sentence><sentence text="Background Purpose of this phase Ib trial was to establish the maximum tolerable dose (MTD) of capecitabine and to escalate the dosages of erlotinib and bevacizumab to determine the recommended phase II dose (RP2D) in patients with advanced/metastatic pancreatic adenocarcinoma not pretreated for metastatic disease"><entity charOffset="95-107" id="DDI-PubMed.29998365.s2.e0" text="capecitabine" /><entity charOffset="139-148" id="DDI-PubMed.29998365.s2.e1" text="erlotinib" /><entity charOffset="153-164" id="DDI-PubMed.29998365.s2.e2" text="bevacizumab" /><pair ddi="false" e1="DDI-PubMed.29998365.s2.e0" e2="DDI-PubMed.29998365.s2.e0" /><pair ddi="false" e1="DDI-PubMed.29998365.s2.e0" e2="DDI-PubMed.29998365.s2.e1" /><pair ddi="false" e1="DDI-PubMed.29998365.s2.e0" e2="DDI-PubMed.29998365.s2.e2" /><pair ddi="false" e1="DDI-PubMed.29998365.s2.e1" e2="DDI-PubMed.29998365.s2.e1" /><pair ddi="false" e1="DDI-PubMed.29998365.s2.e1" e2="DDI-PubMed.29998365.s2.e2" /></sentence><sentence text=" Methods Starting doses were capecitabine 500 mg/m2 bid orally continuously, erlotinib 100 mg orally daily, and bevacizumab 5 mg/kg intravenously q 2 weeks"><entity charOffset="29-41" id="DDI-PubMed.29998365.s3.e0" text="capecitabine" /><entity charOffset="77-86" id="DDI-PubMed.29998365.s3.e1" text="erlotinib" /><pair ddi="false" e1="DDI-PubMed.29998365.s3.e0" e2="DDI-PubMed.29998365.s3.e0" /><pair ddi="false" e1="DDI-PubMed.29998365.s3.e0" e2="DDI-PubMed.29998365.s3.e1" /></sentence><sentence text=" Dose escalation was performed according to a 3 + 3 design for capecitabine until MTD, for erlotinib and bevacizumab until the maximum doses registered by applying a substance-related, toxicity-based scheme accompanied by pharmacokinetic analysis"><entity charOffset="63-75" id="DDI-PubMed.29998365.s4.e0" text="capecitabine" /><entity charOffset="82-85" id="DDI-PubMed.29998365.s4.e1" text="MTD" /><entity charOffset="91-100" id="DDI-PubMed.29998365.s4.e2" text="erlotinib" /><entity charOffset="105-116" id="DDI-PubMed.29998365.s4.e3" text="bevacizumab" /><pair ddi="false" e1="DDI-PubMed.29998365.s4.e0" e2="DDI-PubMed.29998365.s4.e0" /><pair ddi="false" e1="DDI-PubMed.29998365.s4.e0" e2="DDI-PubMed.29998365.s4.e1" /><pair ddi="false" e1="DDI-PubMed.29998365.s4.e0" e2="DDI-PubMed.29998365.s4.e2" /><pair ddi="false" e1="DDI-PubMed.29998365.s4.e0" e2="DDI-PubMed.29998365.s4.e3" /><pair ddi="false" e1="DDI-PubMed.29998365.s4.e1" e2="DDI-PubMed.29998365.s4.e1" /><pair ddi="false" e1="DDI-PubMed.29998365.s4.e1" e2="DDI-PubMed.29998365.s4.e2" /><pair ddi="false" e1="DDI-PubMed.29998365.s4.e1" e2="DDI-PubMed.29998365.s4.e3" /><pair ddi="false" e1="DDI-PubMed.29998365.s4.e2" e2="DDI-PubMed.29998365.s4.e2" /><pair ddi="false" e1="DDI-PubMed.29998365.s4.e2" e2="DDI-PubMed.29998365.s4.e3" /></sentence><sentence text=" Circulating tumor cells (CTCs) were determined pretherapeutically by immunohistochemical identification after enrichment with immunomagnetic separation" /><sentence text=" Results Thirty patients were evaluable at six dose levels" /><sentence text=" 900 mg/m2 bid were determined as MTD for capecitabine based on dose-limiting toxicities: cutaneous in two patients and vascular in another"><entity charOffset="42-54" id="DDI-PubMed.29998365.s7.e0" text="capecitabine" /><entity charOffset="34-45" id="DDI-PubMed.29998365.s7.e1" text="MTD" /><pair ddi="false" e1="DDI-PubMed.29998365.s7.e1" e2="DDI-PubMed.29998365.s7.e1" /><pair ddi="false" e1="DDI-PubMed.29998365.s7.e1" e2="DDI-PubMed.29998365.s7.e0" /></sentence><sentence text=" The most severe (Grade (G)3/4) drug-related treatment-emergent adverse events (toxicities) belonged to the categories gastrointestinal, vascular, cutaneous, cardiovascular, metabolic/nutritional or hematological" /><sentence text=" G3 toxicities occurred in 14 (47%), G3 + G4 in a single (3%) patient" /><sentence text=" 2 out of 28 patients (7%) exerted partial response, 17 (61%) stable disease" /><sentence text=" Pharmacokinetic evaluation revealed lack of drug-drug interaction between capecitabine and erlotinib and their metabolites"><entity charOffset="75-87" id="DDI-PubMed.29998365.s11.e0" text="capecitabine" /><entity charOffset="92-101" id="DDI-PubMed.29998365.s11.e1" text="erlotinib" /><pair ddi="false" e1="DDI-PubMed.29998365.s11.e0" e2="DDI-PubMed.29998365.s11.e0" /><pair ddi="false" e1="DDI-PubMed.29998365.s11.e0" e2="DDI-PubMed.29998365.s11.e1" /></sentence><sentence text=" Presence of CTCs was associated with shorter progression-free survival (p = 0" /><sentence text="009)" /><sentence text=" Conclusions The study met the primary objective" /><sentence text=" RP2D was capecitabine 800 mg/m2 bid continuously, erlotinib 150 mg daily, and bevacizumab 10 mg/kg q 2 weeks"><entity charOffset="10-22" id="DDI-PubMed.29998365.s15.e0" text="capecitabine" /><entity charOffset="51-60" id="DDI-PubMed.29998365.s15.e1" text="erlotinib" /><entity charOffset="79-90" id="DDI-PubMed.29998365.s15.e2" text="bevacizumab" /><pair ddi="false" e1="DDI-PubMed.29998365.s15.e0" e2="DDI-PubMed.29998365.s15.e0" /><pair ddi="false" e1="DDI-PubMed.29998365.s15.e0" e2="DDI-PubMed.29998365.s15.e1" /><pair ddi="false" e1="DDI-PubMed.29998365.s15.e0" e2="DDI-PubMed.29998365.s15.e2" /><pair ddi="false" e1="DDI-PubMed.29998365.s15.e1" e2="DDI-PubMed.29998365.s15.e1" /><pair ddi="false" e1="DDI-PubMed.29998365.s15.e1" e2="DDI-PubMed.29998365.s15.e2" /></sentence><sentence text=" The regimen could be applied safely, but demonstrated limited efficacy" /><sentence text="" /></document>